Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tripartite motif-containing protein 37 (TRIM37) is an E3 ubiquitin ligase and a member of the TRIM family of proteins, characterized by RING, B-box, and coiled-coil domains[1][5]. TRIM37 catalyzes ubiquitination of specific substrate proteins, including histone H2A, modulating transcriptional repression of tumor suppressor genes, and regulates protein assemblies at centrosomes and spindle poles to ensure proper cell division and chromosomal segregation[1][2][3][4]. Germline mutations result in Mulibrey nanism, a multisystem developmental disorder associated with high tumor risk, while somatic copy number gain or overexpression of TRIM37 is linked to aggressive forms of breast cancer and neuroblastoma[1][3][4]. Elevated TRIM37 sensitizes cells to centrinone—a PLK4 inhibitor—providing a potential therapeutic vulnerability in cancer[3]. Loss or dysregulation of this protein is associated with centrosomal abnormalities, genome instability, and altered transcriptional landscapes promoting oncogenesis[1][2][3][4][5].
Centrinone: inhibits PLK4, targeting cells bearing excess TRIM37 and with aberrant centrosome numbers[3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tripartite motif-containing protein 37 (TRIM37).